Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company focused on the development, manufacturing, and commercialization of differentiated pharmaceutical formulations.

As of June 30, 2025, the company had a portfolio of 72 active Abbreviated New Drug Applications (ANDAs) and New Drug Applications (NDAs) approved by the US FDA. Of these, 66 products were commercialized, addressing a US generic pharmaceutical market valued at approximately USD 2,455.7 million, with Rubicon contributing USD 195 million in revenue in Fiscal 2024.

The company also had 17 products awaiting US FDA ANDA approval and 63 products under various stages of development as of June 30, 2025.

Rubicon Research markets over 350 stock-keeping units (SKUs) to 96 customers, including three major wholesalers that collectively account for more than 90% of wholesale drug distribution in the United States. Its customer base also includes group purchasing organizations (GPOs), national and regional pharmacy chains, and managed care organizations.

Outside the US, the company—either directly or through third-party distribution partners—has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates, and expects to commence commercialization upon receiving approvals. Additionally, Rubicon provides contract manufacturing services to select customers in India, Australia, and New Zealand.

Rubicon Research operates three manufacturing facilities in India and two US FDA–inspected R&D facilities, located in India and Canada.

Competitive Strengths:

One of the fastest-growing Indian pharmaceutical companies among its peers

Data-driven product selection framework

Strong research and development capabilities

Robust sales and distribution network in the United States

Proven compliance record combined with cost-effective manufacturing expertise

Experienced and entrepreneurial management team